NYSE:USNA
USANA HEALTH SCIENCES INC
A direct-selling health and wellness giant with strong cash generation but facing recent revenue contraction.
Key Metrics
Investment Thesis
Bull Case
USANA possesses a resilient balance sheet with $181.8M in cash equivalents covering current liabilities, offering potential for strategic pivots or dividend growth if operational efficiency improves; the company's high gross profit of $693.3M suggests strong pricing power and product demand despite volume headwinds.
Bear Case
The consistent year-over-year decline in both revenue and net income over the last three years signals a deteriorating business trajectory that may persist without new growth drivers; large non-cash adjustments of $22.0M and significant other cash flow outflows of -$426.5M raise concerns about underlying cash burn or aggressive accounting tactics.
About USANA HEALTH SCIENCES INC
USANA Health Sciences Inc. is a leading global wellness and nutrition company specializing in multi-level marketing distribution of health supplements, personal care products, and home care solutions primarily serving the North American market.
Analysis
Management Discussion
Despite generating positive operating profit of $66.3M, net income dropped sharply to $42.1M in 2024, mirroring a revenue contraction from nearly $1B in 2022 to $854.5M; the company maintained robust cash flow from operations at $61.0M but utilized significant capital for acquisitions totaling $203.3M and saw cash reserves decline by over $148M.
Industry Overview
The global direct selling and health supplement industry is valued at hundreds of billions but faces increasing regulatory scrutiny and competition from e-commerce retailers; consumers are shifting towards transparent, science-backed brands while distribution models adapt to digital engagement requirements.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Revenue | $998.6M | $921.0M | $854.5M |
| Cost of Revenue | $193.9M | $176.7M | $161.2M |
| Gross Profit | $804.7M | $744.3M | $693.3M |
| Operating Expenses | $697.1M | $651.2M | $627.0M |
| Operating Income | $107.6M | $93.1M | $66.3M |
| R&D | $11.6M | $11.4M | $11.6M |
| G&A | $262.3M | $257.0M | $263.3M |
| Stock-Based Comp | $13.3M | $14.6M | $14.6M |
| D&A | $13.4M | $12.7M | $14.5M |
| Depreciation | $11.4M | $10.9M | $13.2M |
| Amortization | $1.7M | $1.8M | $1.5M |
| Other OpEx | $423.2M | $382.8M | $352.1M |
| Non-Operating Income | $1.0M | $9.4M | $10.0M |
| Interest Expense | $192.0K | $262.0K | — |
| Interest Income | $3.8M | $9.6M | $11.3M |
| Pre-Tax Income | $108.6M | $102.5M | $76.4M |
| Income Tax | $39.3M | $38.7M | $34.3M |
| Continuing Ops | $69.3M | $63.8M | $42.1M |
| Discontinued Ops | $0 | $0 | $0 |
| Net Income | $69.3M | $63.8M | $42.1M |
| Minority Interest | $0 | $0 | $0 |
| Net to Common | $69.3M | $63.8M | $42.1M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Current Assets | $384.4M | $417.7M | $279.2M |
| Cash & Equivalents | $288.4M | $330.4M | $181.8M |
| Inventory | $67.1M | $61.5M | $69.7M |
| Prepaid Expenses | $28.9M | $25.9M | $27.7M |
| Other Current Assets | $0 | $0 | $0 |
| Long-Term Assets | $212.2M | $215.0M | $469.0M |
| PP&E (Net) | $97.8M | $99.8M | $94.6M |
| Intangibles | $32.4M | $29.9M | $151.8M |
| Goodwill | $17.4M | $17.1M | $144.2M |
| Operating Leases | $20.0M | $17.7M | $21.2M |
| Other LT Assets | $44.6M | $50.5M | $57.3M |
| Total Assets | $596.5M | $632.8M | $748.2M |
| Current Liabilities | $143.8M | $118.8M | $139.6M |
| Accounts Payable | $11.0M | $10.1M | $12.0M |
| Current Leases | $6.9M | $7.3M | $6.0M |
| Taxes Payable | $5.0M | $3.3M | $3.7M |
| Other Current Liab | $120.9M | $98.2M | $104.3M |
| Long-Term Liabilities | $18.2M | $16.7M | $22.2M |
| LT Operating Leases | $7.7M | $5.1M | $10.2M |
| Other LT Liab | $10.6M | $10.8M | $-11.0M |
| Total Liabilities | $162.1M | $135.6M | $161.9M |
| Shareholders' Equity | $434.5M | $497.2M | $586.3M |
| Retained Earnings | $391.6M | $445.2M | $478.9M |
| AOCI | $-12.8M | $-13.7M | $-22.7M |
| Total L&E | $596.5M | $632.8M | $748.2M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Net Income (CFO) | $69.3M | $63.8M | $42.1M |
| Non-Cash Adjustments | $64.8M | $39.8M | $22.0M |
| Working Capital Changes | $-30.3M | $-32.9M | $-3.0M |
| Cash from Operations | $103.9M | $70.6M | $61.0M |
| Capital Expenditures | $10.4M | $14.5M | $10.1M |
| Cash from Investing | $-12.4M | $-12.0M | $-213.1M |
| Share Buybacks | $25.4M | $11.6M | $9.4M |
| Cash from Financing | $-30.1M | $-14.2M | $9.6M |
| FX Effect | $-13.8M | $-2.5M | $-6.2M |
| Net Change in Cash | $47.7M | $41.9M | $-148.7M |
| Beginning Cash | $243.7M | $291.3M | $333.2M |
| Ending Cash | $291.3M | $333.2M | $184.5M |
Frequently Asked Questions
How does USANA HEALTH SCIENCES INC make money?
The company operates through three primary segments: Nutrition (dietary supplements), Personal Care (cosmetics and hygiene products), and Home Care (cleaning and laundry solutions), all distributed via a direct-to-consumer multi-level marketing model.
What are the main risks for USNA?
Significant revenue decline over the past three years indicates potential demand saturation or distribution channel weakness; heavy reliance on direct-selling performance which can be volatile; substantial accumulated retained earnings deficit suggesting historical profitability challenges or aggressive growth spending.
What is USNA's competitive advantage?
USANA leverages a highly engaged distributor network providing extensive market penetration, proprietary clinically tested product formulations with high gross margins, and strong brand loyalty within the natural health sector.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.